Actively Recruiting

Phase Not Applicable
Age: 18Years - 80Years
All Genders
NCT06629116

Study on the Role of Human Serum Albumin in Large Acute Ischemic Stroke of Anterior Circulation After Thrombectomy

Led by Tingyu-Yi · Updated on 2024-10-08

100

Participants Needed

1

Research Sites

173 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This project intends to explore the therapeutic efficacy of human serum albumin in mitigating postoperative cerebral edema and enhancing clinical outcomes following mechanical thrombectomy in patients with acute anterior circulation large-core ischemic stroke.

CONDITIONS

Official Title

Study on the Role of Human Serum Albumin in Large Acute Ischemic Stroke of Anterior Circulation After Thrombectomy

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18-80 years old.
  • Acute ischemic stroke patients with NIHSS score 64 6.
  • Pre-stroke modified Rankin Scale (mRS) score 64 1.
  • Symptom onset to presentation within 24 hours, including wake-up or unwitnessed strokes.
  • Confirmation by CTA, MRA, or DSA of anterior circulation large vessel occlusive ischemic stroke.
  • ASPECTS score on non-contrast CT between 3 and 6, or core infarct volume 50-100 ml on perfusion imaging.
  • Achieved vessel reperfusion with mTICI grade 2b or 3 by mechanical thrombectomy.
  • Written informed consent provided by the patient or legal representative.
Not Eligible

You will not qualify if you...

  • Intracranial hemorrhage confirmed by CT or MRI.
  • Pre-stroke modified Rankin Scale (mRS) score greater than 2.
  • Severe allergy or contraindication to iodine-based contrast agents.
  • Uncontrolled high blood pressure with systolic >185 mmHg or diastolic >110 mmHg.
  • Blood glucose levels below 50 mg/dl or above 400 mg/dl that are difficult to correct.
  • Bleeding disorders, coagulation factor deficiency, or oral anticoagulation with INR >1.7.
  • Severe kidney dysfunction or need for dialysis.
  • Expected life expectancy less than 6 months.
  • Inability to complete 90-day follow-up.
  • Suspected aortic dissection.
  • Brain tumors, aneurysms, or arteriovenous malformations with mass effect.
  • Neurological or psychiatric conditions affecting stroke assessment.
  • Pregnancy or positive beta-HCG test.
  • Participation in other interfering clinical trials.
  • History of allergy to albumin.
  • Need for ongoing treatment of acute or chronic lung diseases.
  • Congestive heart failure in past 6 months or related treatments.
  • Recent or symptomatic acute myocardial infarction within 6 months.
  • Any other conditions deemed unsuitable or risky by investigators.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Zhangzhou Municipal Hospital

Zhangzhou, Fujian, China, 363000

Actively Recruiting

Loading map...

Research Team

T

Tingyu Yi, Postgraduate

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here